Modus Therapeutics Investor Relations Material
Latest events
Q2 2025
Modus Therapeutics
Q2 2025
7 Aug, 2025
Q1 2025
14 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Modus Therapeutics Holding
Access all reports
Modus Therapeutics Holding is a clinical-stage biopharmaceutical company developing therapies for diseases related to inflammation and blood flow disorders. Its lead programs focus on treatments for conditions such as sepsis and sickle cell disease. The company is headquartered in Stockholm, Sweden, and its shares are listed on the Nasdaq First North Growth Market.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
MODTX
Country
🇸🇪 Sweden